ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Benjamin P Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.